Menu Close

Trending

Merck snaps up cancer drug from China’s Kelun in $1.4bn deal
SwanBio raises $56m for rare neurological disease gene therapy
KOL Validation: An Opportunity To Benchmark Mindset
Digital health body publishes best practice guide for DTx developers
AstraZeneca buys into startup RQ Bio’s COVID antibodies

cancer treatment

eye-on-innovation-16x9-V-Bainton

Oncology/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

Communication problems holding back new cancer treatments 

, , , , 0 Comment

Cancer immunotherapy is revolutionising oncology – but the Havas Lynx Group’s chief medical officer Vernon Bainton argues that the incredible progress is

X
Communication problems holding back new cancer treatments 
https://pharmaphorum.com/oncology/communication-problems-holding-back-new-cancer-treatments/
Oncolytics

ASCO 2018/ Event coverage/ Oncology/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

Oncolytics: the dawn of a new era in cancer treatment

, , , , , 0 Comment

Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major

X
Oncolytics: the dawn of a new era in cancer treatment
https://pharmaphorum.com/views-analysis-oncology/oncolytics-new-era-cancer-treatment/
Mesoblast stem cell therapy GVHD

Clinical/ Oncology/ Partner Content/ Partner content/ Press releases/ Quintiles/ Quintiles - ContentIO

Overcoming the five challenges to effective immuno-oncology trials

, , , , , , , 0 Comment

Recent advances have seen immuno-therapy become a shining light within oncology research, transforming both the way cancer treatments

X
Overcoming the five challenges to effective immuno-oncology trials
https://pharmaphorum.com/partner-content-oncology/beware-octo-trial/

Login

CONTINUE TO SITE >
X
Close in 10 seconds